4.4 Article

Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis

期刊

CLINICAL RHEUMATOLOGY
卷 40, 期 3, 页码 941-948

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s10067-020-05343-6

关键词

CD163; Lupus nephritis; M2 macrophages; Macrophages; Renal SLEDAI; Urinary biomarkers

资金

  1. Dept. of Biotechnology, Government of India research grant [BT/PR15397/MED/30/604/2011]
  2. India RheumatologyAssociation (IRA)

向作者/读者索取更多资源

Urinary sCD163 is a promising biomarker for assessing disease activity in lupus nephritis, showing significantly higher levels in active LN patients and correlating with renal SLEDAI. In follow-up studies, urinary sCD163 levels decreased gradually in active LN patients and correlated with disease activity changes, suggesting its potential for monitoring disease progression.
Objectives Activated macrophages expressing CD163 (M2) are the most abundant macrophage subtype in renal biopsies from lupus nephritis (LN) patients. We studied the role of proteolytically cleaved soluble CD163 (sCD163) as a biomarker of LN disease activity. Methods SLE patients were classified as active LN (AN), inactive disease (ID), and active non-renal disease (ANR). Urine and plasma samples were collected at baseline from all patients and at 3 monthly follow-up from AN patients. sCD163 was measured by ELISA. Urine values were normalized to urinary creatinine excretion and expressed as pg/mg. Urine samples from 25 healthy controls (HC) and 20 rheumatoid arthritis patients served as disease controls (DC). Results Among the 122 patients studied (114 females, 57 AN, 42 ID, 23 ANR), baseline median urinary sCD163 in the AN group (114.01 pg/mg) was significantly higher (p < 0.001) as compared with ID (10.34 pg/mg), ANR (3.82 pg/mg), HC (0 pg/mg), and DC (7.56 pg/mg) groups and showed modest correlation with renal SLEDAI (r = 0.47;p < 0.001). Urinary sCD163 performed the best on receiver operating characteristics (ROC) analysis (AUC = 0.76) at baseline to differentiate between AN and ANR as compared with plasma sCD163, anti-ds DNA antibodies, and C3 and C4. In follow-up study, urinary sCD163 decreased significantly (p < 0.001) in AN patients at 3 (22.07 pg/mg), 6 (12.7 pg/mg), 9 (11.09 pg/mg), and 12 months (7.2 pg/mg). In 4 patients who had either relapse or developed CKD, urinary sCD163 levels correlated with the changing disease activity. Conclusions Urinary sCD163 is a good biomarker of LN disease activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据